Changes this week
Changes detected in the 7 days to Nov 20, 2026
- Minor: Revaccination With a Vaccine Called RSVpreF in Older Adults Trial sites expanded: 0 → 13 locations
- Minor: SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE) Trial sites expanded: 7 → 13 locations
- Minor: IGNITE · Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Trial sites expanded: 42 → 50 locations
- Minor: Symbiotic-GI-03 · PF-08634404 in Combination With Chemotherapy · Metastatic Colorectal Cancer Trial sites expanded: 372 → 401 locations
- Minor: Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy · Locally Advanced or Metastatic Non-Small Cell Lung Cancer Trial sites expanded: 484 → 560 locations
- Minor: Induction Study to Investigate the Efficacy and Safety of Duvakitug · Moderately to Severely Active Ulcerative Colitis Trial sites expanded: 240 → 265 locations
- Minor: Induction Study to Investigate the Efficacy and Safety of Duvakitug · Moderately to Severely Active Crohn's Disease Trial sites expanded: 461 → 481 locations
- Minor: Symbiotic-GI-16 · PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer Trial sites expanded: 100 → 124 locations
- Minor: Upadacitinib · Alopecia Areata Trial sites expanded: 13 → 22 locations
- Minor: NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness Trial sites expanded: 4 → 7 locations
- Minor: Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer Trial sites expanded: 200 → 209 locations
- Minor: Intravenous Anifrolumab · Systemic Lupus Erythematosus in Pediatric Participants Trial sites expanded: 103 → 111 locations
- Minor: Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects Trial sites expanded: 93 → 97 locations
- Minor: Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder Trial sites reduced: 62 → 56 locations
- Minor: Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma Trial sites expanded: 1 → 11 locations
- Minor: Pegozafermin · MASH and Fibrosis (ENLIGHTEN-Fibrosis) Trial sites expanded: 370 → 375 locations
- Minor: Maintenance Study to Investigate the Efficacy and Safety of Duvakitug · Moderately to Severely Active Crohn's Disease Trial sites expanded: 109 → 152 locations
- Minor: Rimegepant in Adults When Used · Chronic Migraine Trial sites expanded: 19 → 38 locations
- Minor: Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures Trial sites reduced: 136 → 133 locations
- Minor: Momelotinib · Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome Trial sites expanded: 0 → 3 locations
- Minor: Oral Levosimendan Trial sites expanded: 9 → 14 locations
- Minor: Pimicotinib · Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) Trial sites expanded: 4 → 7 locations
- Minor: Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment · Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Trial sites expanded: 3 → 9 locations
- Minor: VS-7375 · KRAS G12D-Mutated Non-Small Cell Lung Cancer Trial sites expanded: 24 → 27 locations
- Minor: Symbiotic-GU-08 · PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies · Locally Advanced or Metastatic Renal Cell Cancer Trial sites expanded: 183 → 186 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates